- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05776862
Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
April 22, 2024 updated by: Mark S. Nash, Ph.D., FACSM, University of Miami
A Pilot Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
This study will evaluate if Ursolic Acid supplementation may be effective in reducing muscle loss and improving blood sugar control in the SCI community.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patricia Graham, MS
- Phone Number: 3052435119
- Email: pgraham1@med.miami.edu
Study Contact Backup
- Name: Mark S Nash, PhD
- Phone Number: 305.243.3628
- Email: mnash@med.miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami - Miami Project to Cure Paralysis
-
Contact:
- Mark S Nash, PhD
- Phone Number: 305-243-3628
- Email: mnash@med.miami.edu
-
Contact:
- Patricia Graham, MS, CCRC
- Phone Number: 305-243-5119
- Email: pgraham1@med.miami.edu
-
Principal Investigator:
- Mark S Nash, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male and female individuals with paraplegia having chronic (> 1 year) motor-complete and incomplete (AIS A/B/C) injuries from T2-T8
- Male and female individuals wi4.th chronic (> 1 year) motor-complete and incomplete (AIS A/B/C) injuries from C4-C7
Exclusion Criteria:
- Pregnant or planning to become pregnant
- Women who are breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UA and exercise in paraplegia group
Participants will take UA 4 capsules twice daily for 12 weeks while participating in an exercise program, 3 times per week.
|
Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session.
Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets.
The arm selected for exercise will be randomized.
|
Experimental: UA in tetraplegia group
Participants will take UA 4 capsules twice daily for 12 weeks
|
Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in muscle mass using Dual X-ray Absorptiometry (DXA)
Time Frame: Baseline, 12 weeks
|
Changes in muscle mass as measured by Dual X-ray Absorptiometry
|
Baseline, 12 weeks
|
Changes in muscle mass using Computed Tomography (CT) scans
Time Frame: Baseline, 12 weeks
|
Changes in muscle mass as measured by CT scans
|
Baseline, 12 weeks
|
Changes in peak isokinetic strength
Time Frame: Baseline, 12 weeks
|
Peak strength of both arms at 90 degrees of flexion will be tested in elbow flexion and extension on a Biodex dynamometer
|
Baseline, 12 weeks
|
Changes in fasting insulin resistance (IR)
Time Frame: Baseline, 12 weeks
|
Changes in IR using Homeostatic Model of Assessment (HOMA) v2 model estimates steady state beta cell function and insulin sensitivity as percentages of a normal reference population.
The change in resting IR will be measured by (fasting serum glucose*fasting serum insulin/22.5).
Lower values indicate a higher degree of insulin sensitivity.
|
Baseline, 12 weeks
|
Changes in glucose disposal
Time Frame: Baseline, 12 weeks
|
Changes in glucose disposal will be measured by the Oral Glucose Tolerance Test (OGTT) using Trutol glucose solution of 75 grams.
The rates of glucose disposal will be defined by the area under the glucose challenge curve (AUC).
|
Baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark S Nash, PhD, University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2023
Primary Completion (Estimated)
May 1, 2025
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
March 7, 2023
First Submitted That Met QC Criteria
March 7, 2023
First Posted (Actual)
March 20, 2023
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Trauma, Nervous System
- Spinal Cord Diseases
- Hyperinsulinism
- Atrophy
- Paralysis
- Wounds and Injuries
- Insulin Resistance
- Muscular Atrophy
- Spinal Cord Injuries
- Quadriplegia
- Paraplegia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Ursolic Acid
Other Study ID Numbers
- 20221142
- COPBC (Other Identifier: State of Florida)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin ResistanceUnited States
-
Paloma Almeda-ValdésCompleted
-
German Diabetes CenterYale UniversityRecruiting
-
National Institute of Diabetes and Digestive and...Active, not recruitingSevere Insulin ResistanceUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Assiut UniversityCompleted
-
National Taiwan UniversityNational Cheng-Kung University HospitalCompletedExercise, Insulin Resistance, Visceral Adipose TissueTaiwan
-
University Health Network, TorontoCompletedInsulin Resistance Syndrome X | Pancreatic Beta Cell FunctionCanada
-
The University of Texas Medical Branch, GalvestonCompletedInsulin Resistance, DiabetesUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
Clinical Trials on Ursolic Acid
-
The University of Texas Health Science Center at...CompletedBioavailability of PhytonutrientsUnited States
-
The University of Texas Health Science Center at...WithdrawnProstate CancerUnited States
-
University of California, DavisWithdrawnPrimary Sclerosing CholangitisUnited States
-
University of GuadalajaraCompletedMetabolic Syndrome XMexico
-
Russell SwerdlowCompleted
-
Vanderbilt UniversityNational Cancer Institute (NCI)CompletedColorectal Adenomatous PolypsUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedHealthy VolunteersBelgium
-
Dr. Falk Pharma GmbHRecruiting
-
Société des Produits Nestlé (SPN)Completed
-
Syracuse UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedEssential Voice Tremor | Voice Tremor | Vocal Tremor | Essential Tremor of VoiceUnited States